Get Involved
Australian & New Zealand Childrens Haematology/Oncology Group

Clinical Trials

Far-RMS: Frontline and Relapse Study in RhabdomyoSarcoma Study

Rhabdomyosarcoma

Status: In Development

Patients diagnosed with rhabdomyosarcoma are treated with chemotherapy, radiotherapy and surgery, but many do not survive. Our United Kingdom and European colleagues have developed a new overarching trial, FaR-RMS study, which includes optimising radiotherapy, testing the latest promising agents, new combinations and analysing the length of therapy. Several research questions are addressed within FaR-RMS and new drugs can be rapidly added. Opening Far-RMS in Australia gives new hope to all patients battling rhabdomyosarcoma.

Disease Stage: Newly diagnosed, relapsed and progressive

Patient Age Range: All ages

Recruitment Period: Up to 7 years

Trial Sponsors:

  • International: University of Birmingham
  • National: ANZCHOG

ANZCHOG acknowledges the valuable support of Far-RMS by the Australian Government through the Medical Research Future Fund.

logo-australian-gov.png